Enumeral Biomedical (ENUM) 0.2000 $ENUM Enumeral

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2016 at 7:16 PM

Enumeral Biomedical (ENUM) 0.2000 $ENUM

Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement
BusinessWire - Mon Jun 06, 5:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"

, it has received a $750,000 license maintenance fee from and entered into a Definitive License and Transfer Agreement (the "Definitive Agreement"

with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris"

to continue Pieris' license to Enumeral's 388D4 anti-PD-1 antibody.

Enumeral Reports First Quarter Financial Results
BusinessWire - Fri May 13, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the three months ended March 31, 2016.

Enumeral Announces Additional Data on Its Novel Class of PD-1 Antagonist to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
BusinessWire - Mon Apr 18, 7:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it will present research findings on the Company's novel class of anti-PD-1 antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans.

Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement
BusinessWire - Mon Apr 18, 5:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, "Pieris"

.
PIRS: 1.72 (+0.02)

Enumeral to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
BusinessWire - Thu Mar 31, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit at 3:25 pm Eastern Time in the North Atlantic Room of the Boston Harbor Hotel on Thursday, April 7, 2016. The Summit is being held at the Boston Harbor Hotel, Boston Massachusetts, on April 7-8, 2016.

Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results
BusinessWire - Wed Mar 30, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2015.

Enumeral to Present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference
BusinessWire - Tue Jan 19, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference on Wednesday, January 20, 2016 at 10:00 am Eastern Time. In addition, Dr. Tinkelenberg will be participating in a panel discussion entitled "The Brave New World of Cancer Immunotherapy" at 5:15 pm Eastern Time on Tuesday, January 19, 2016. The conference is being held at the Club Med in Sandpiper Bay, FL.

Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement
BusinessWire - Mon Jan 11, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) today announced that it has entered into a Collaborative Research and Development Agreement with The University of Texas MD Anderson Cancer Center.

Enumeral Presents Research Results for Novel Class of Anti-PD-1 Antibodies at AACR's 2016 Tumor Microenvironment Special Conference
BusinessWire - Fri Jan 08, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced the presentation of research findings for the Company's novel class of anti-PD-1 antibodies at the Function of the Tumor Microenvironment in Cancer Progression Conference, sponsored by the American Association for Cancer Research (AACR) and taking place in San Diego, CA, from January 7-10, 2016. Enumeral is advancing a novel class of potentially allosteric anti-PD-1 antibodies with distinctive properties compared to currently marketed anti-PD-1 antagonists, including a mechanism of action that does not appear to require the disruption of PD-1 interaction with PD-L1.

Enumeral to Participate in the 2016 East/West CEO Conference
BusinessWire - Wed Jan 06, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will participate in the 2016 East/West CEO Conference on the panel entitled "Academia and Industry: Challenges and Synergies," on Sunday, January 10, 2016 at 1:30 p.m. Pacific Time. The conference will be held at the Four Seasons Hotel in San Francisco, CA.

Enumeral to Present at Biotech Showcase 2016
BusinessWire - Tue Jan 05, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral's President and Chief Executive Officer, will present a corporate overview at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 9:30 a.m. Pacific Time at the Parc 55 Hotel in San Francisco, CA.

Enumeral to Present at the Oppenheimer 26th Annual Healthcare Conference
BusinessWire - Tue Dec 01, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8th, 2015 at 3:20 p.m. ET at The Westin New York Grand Central Hotel in New York City.

Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update
BusinessWire - Tue Nov 10, 3:30PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended September 30, 2015.

Enumeral Reports That Its Novel Class of Anti-PD-1 Antibodies Elicits Higher T Cell Activation in Ex Vivo Human Assays than Currently Marketed Anti-PD-1 Antibodies
BusinessWire - Tue Nov 03, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral researchers have demonstrated greater functional activity of its novel class of anti-PD-1 antibodies (as measured by restoration of T cell function in cell-based assays) when compared to conventional anti-PD-1 antibodies that disrupt PD-1 interaction with PD-L1. Enumeral's potentially allosteric antibodies block PD-L1-mediated immunosuppression, but do not disrupt PD-1 interaction with PD-L1.

Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center
BusinessWire - Mon Oct 05, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that the company will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at The University of Texas MD Anderson Cancer Center's Emerging Concepts in Host Response to Cancer Symposium Symposia. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster will be presented at MD Anderson Cancer Center's R. Lee Clark Clinic, 1515 Holcombe Boulevard, Floor 11, in Houston, Texas on October 8, 2015.

Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
BusinessWire - Thu Sep 24, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced important progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 and LAG-3 antibody programs.

Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015
BusinessWire - Fri Sep 11, 7:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Enumeral will present a poster titled "Human Tumor-Based Identification of Immune Checkpoint Targets" at the International Cancer Immunotherapy Conference. Enumeral's poster will highlight recent developments in the company's PD-1 and TIM-3 antibody programs. The poster number is B083, and will be presented in the Empire Ballroom at the Sheraton New York Times Square Hotel in New York City from 4:45 pm to 6:45 pm on September 18, 2015.

Enumeral Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Aug 12, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" or the "Company"

, a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015.

Enumeral Appoints Robert J. Easton to its Board of Directors
BusinessWire - Thu Jul 30, 3:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-Chairman of Bionest Partners, Inc., a consulting firm he co-founded that specializes in strategic planning for pharmaceutical, medical device and diagnostic companies.

Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs
BusinessWire - Tue Jul 14, 7:45AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company's R&D pipeline, including its TIM-3 antibody program.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ONLYOFFICE 10.0 Boosts AI and Security Features

A Fresh Look at ONLYOFFICE 10.0's Game-Changing Update Outta the gates swinging, ONLYOFFICE dropped their latest 10.0 update. This one ain't just your average software facelift—it's packing some serious heat with AI enhancements, brand spanking new modular apps, and beefed-up security features that'll make anyone dealing with sensitive data breathe a little easier. AI...

Young Visionaries Win Junior Medals at STARMUS VIII

Fresh from the Canary Islands' shores, STARMUS VIII has lifted the veil on two young powerhouses shaping tomorrow—Valeria Corrales and Aneeshwar Kunchala. These two have snagged coveted honors, crowning them as champions of their generation. Igniting Passion for Science and the Environment Valeria Corrales isn't just another face in the crowd; she’s the force behind a...

AI Revenue Missteps Shake Semiconductor Stocks

Nervous Times for Semiconductor Stocks When the semiconductor sector started October like a high-speed train, I thought we might sail through this month without hitting turbulence. But then, in trotted some shaky AI revenue numbers, and bam, the whole sector took a hit off its October highs. The semiconductor stocks, led by giants like Taiwan Semiconductor Manufacturing...

AI in Music: CITY JAM Focuses on Human Creativity

Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...

Jiangxi Dialogues: Youths Forge Global Ties in 2026

Bringing Global Youth to the Table In the heart of Jiangxi, China, young minds from across the globe gathered not just to chat but to shape the future. A bunch who only a decade ago might have been ignored in such circles are now leading discussions, and they’ve kicked off their powwow on September 22, 2026, with a bang in Nanchang. What’s the Agenda? Imagine more...

KAPSARC Drives Energy Dialogue at WPC in Riyadh

Defining Energy Horizons in Riyadh Mark those calendars, because as the global energy crowd descends on Riyadh from October 11 to 15, 2026, KAPSARC steps into the spotlight. As the National Partner at the 25th World Petroleum Congress (WPC), they're not just warming the bench—they're playing every position, shaking up the field of energy. Paving the Pathways with...

Tchah Sup Kim: A Retrospective at KCCNY in 2026

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...

Amap, Sands China Unleash Tutu Robots for Resort Duty

Tutu Robots Usher in a New Technological Era for Sands China Alright, let's dive into some tech that feels out of a sci-fi movie and see what Sands China and Amap have cooked up as they introduce the Tutu robot dogs to Sands Resorts Macau. These aren't your run-of-the-mill gadgets—they're futuristic tour guides ready to rewire visitor experiences. The delivery ceremony...

RingConn Smart Ring Gains Key FDA 510(k) Clearance

FDA Clearance: A Major Step for RingConn In a space where every tiny gadget-maker is desperately clawing for a regulatory nod, RingConn—a venture born from Shenzhen Ninenovo Technology Limited—has snagged an FDA 510(k) clearance (Clearance No. K260490) for their wearable Smart Ring that measures blood oxygen levels non-invasively. October 10, 2026, marked the day when...

Haag-Streit Debuts Innovative Octopus 910 Perimeter at AAO

Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...